Sustained-Release Prostate Injection for Minimally Invasive BPH Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Benign Prostatic Hyperplasia (BPH) are invasive, have long onset times, and carry significant side effects, necessitating a less invasive and more effective approach with reduced side effects.

Innovation Solution

A sustained release formulation (SRF) is administered directly to the prostate via minimally invasive methods like transurethral, transrectal, or transperineal approaches, using a delivery vehicle to provide a cytostatic or cytotoxic drug in a controlled release manner, minimizing urethra damage and side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If oral medications are used to treat BPH, then the treatment can be administered easily, but the onset time is long and side effects occur

Engineering Contradiction:

Improveease of administrationVSAvoidonset time

Core Design Contradiction:

Ease of operationVSLoss of time

Solution Approach 1:

The active drug substance is extracted from systemic circulation and delivered directly to the prostate target tissue through injection, eliminating the need for oral administration and achieving immediate local effect without systemic distribution delays

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

A biodegradable sustained release formulation acts as an intermediary carrier that delivers the drug directly to the prostate, providing both immediate availability and prolonged local action while avoiding first-pass metabolism and systemic side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If invasive surgical procedures are used to treat BPH, then the efficacy is improved, but the trauma to the urethra and side effects increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidurethra damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The treatment applies high drug concentration locally to the prostate tissue through direct injection, achieving effective BPH treatment without the need for invasive surgical intervention that would traumatize the urethra

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The mechanical invasive surgical system is replaced with a minimally invasive injection system that delivers therapeutic agents directly to the target tissue, eliminating physical trauma to surrounding structures while maintaining treatment efficacy

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Duration of action of stationary object

If frequent injections are used to maintain treatment effect, then the sustained efficacy is improved, but the procedure complexity and patient burden increase

Engineering Contradiction:

Improvesustained efficacy durationVSAvoidinjection frequency

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The biodegradable sustained release formulation provides continuous drug release over an extended period following a single injection, maintaining therapeutic efficacy without requiring repeated administration procedures

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The drug is pre-loaded into a biodegradable carrier system that is then injected once into the prostate, where it automatically releases the drug over time, eliminating the need for multiple injection procedures

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentEP4216926B1System and method for prostate treatment

Publication Date: 2026.03.04 RESURGE THERAPEUTICS INC

Figure 1~2
Figure 3
Figure 4

AI summary

A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and up to about 12 months.